Literature DB >> 9643737

Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease.

J G Nutt1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9643737     DOI： 10.1016/S0140-6736(05)79311-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

Review 1.  Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.

Authors:  S Kaakkola
Journal:  Drugs       Date:  2000-06       Impact factor: 9.546

2.  Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.

Authors:  T Müller; C Erdmann; S Muhlack; D Bremen; H Przuntek; O Goetze; D Woitalla
Journal:  J Neural Transm (Vienna)       Date:  2006-04-11       Impact factor: 3.575

3.  Clinical Pharmacology of Entacapone (Comtan) From the FDA Reviewer.

Authors:  Sam Habet
Journal:  Int J Neuropsychopharmacol       Date:  2022-08-04       Impact factor: 5.678

4.  Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.

Authors:  D J Brooks; H Sagar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-08       Impact factor: 10.154

5.  Initial treatment of Parkinson's disease.

Authors:  Daniel Tarsy
Journal:  Curr Treat Options Neurol       Date:  2006-05       Impact factor: 3.972
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.